Detail akcie Valneva SE online

Business Summary: Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Valneva SE revenues increased 10% to EUR169.6M. Net loss decreased 88% to EUR12.2M. Revenues reflect Commercialized products segment increase of 18% to EUR163.3M, United States segment increase of 47% to EUR48.6M, Germany segment increase of 36% to EUR18.4M. Lower net loss reflects General and administrative expenses - Ba decrease of 11% to EUR42.1M (expense).